Table of Contents

Tibotec

Tibotec was a biopharmaceutical company based in Belgium.

Activities

Tibotec was acquired by Johnson & Johnson in April 2002.1)

Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda, including trials involving David Boulware.2) 3)

The company was renamed to Janssen Therapeutics in June 2011.4)

1)
Johnson & Johnson to Acquire Tibotec-Virco. (2002, March 22). Johnson & Johnson. https://web.archive.org/web/20020608123005/http://www.investor.jnj.com/ReleaseDetail.cfm?ReleaseID=75177
2)
Clinical Research at the Infectious Diseases Institute. The Global Health Network; Infectious Diseases Institute. Retrieved May 17, 2023, from https://web.archive.org/web/20230517060735/https://media.tghn.org/site_finder/sites/documents/Clinical_Research_at_IDI.pdf
3)
Schmickle, S. (2008, November 13). University of Minnesota doctors battle AIDS in Uganda. MinnPost. http://archive.today/2010.06.23-113510/http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda
4)
Van Houten, P. (2011, June 22). Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies. Johnson & Johnson. http://archive.today/2023.05.17-061755/https://www.jnj.com/media-center/press-releases/tibotec-therapeutics-becomes-janssen-therapeutics-part-of-the-janssen-pharmaceutical-companies